Drug Trial Radar · NCT01618370
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Last checked: Nov 20, 2026Latest source record: Mar 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
705
Actual
Start
Jul 22, 2012
Primary completion
Aug 13, 2014
Study completion Feb 28, 2016
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jun 13, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product.
Conditions
- Prostatic Neoplasms
Interventions
Radium-223 dichloride (BAY88-8223)Drug
One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acute safety, variables will be summarized using descriptive statistics based on adverse events collectionTime frame: From baseline to 30 days post-treatment
- Long-term safety, variables will be summarized using descriptive statistics based on adverse events collectionTime frame: From 30 days post-treatment up to 3 years
Locations
215 sites in 19 countries. Site status is shown where the registry gives one.
Site not named
Bruges, Belgium
Site not named
Bruxelles - Brussel, Belgium
Site not named
Bruxelles - Brussel, Belgium
Site not named
Bruxelles - Brussel, Belgium
Site not named
Edegem, Belgium
Site not named
Ghent, Belgium
Site not named
Kortrijk, Belgium
Site not named
Leuven, Belgium
Site not named
Ottignies, Belgium
Site not named
Edmonton, Alberta, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Brno, Czechia
Site not named
Ostrava, Czechia
Site not named
Plzen - Bory, Czechia
Site not named
Prague, Czechia
Site not named
Prague, Czechia
Site not named
Copenhagen, Denmark
Site not named
Herlev, Denmark
Site not named
Odense, Denmark
Site not named
Helsinki, Finland
Site not named
HUS, Finland
Site not named
Kuopio, Finland
Site not named
Seinäjoki, Finland
Site not named
Tampere, Finland
Site not named
Angers, France
Site not named
Avignon, France
Site not named
Caen, France
Site not named
Clermont-Ferrand, France
Site not named
Grenoble, France
Site not named
La Roche-sur-Yon, France
Site not named
Lille, France
Site not named
Lille, France
Site not named
Montpellier, France
Site not named
Montpellier, France
Site not named
Paris, France
Site not named
Paris, France
Showing 40 of 215 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.